Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
Status:
Completed
Trial end date:
2009-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a
combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer
(TCC) of the urothelial tract. The primary endpoint was to assess response, as defined as a
25% reduction in measurable disease per the RECIST criteria. Measurable or evaluable
objective response rate, time to disease progression and survival were also assessed.